[HTML][HTML] Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo …
SH Khoo, R FitzGerald, G Saunders… - The Lancet Infectious …, 2023 - thelancet.com
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
[PDF][PDF] Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo …
SH Khoo, R FitzGerald, G Saunders, C Middleton… - Lancet Infect …, 2023 - researchgate.net
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
[HTML][HTML] Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo …
SH Khoo, R FitzGerald, G Saunders… - The Lancet Infectious …, 2023 - Elsevier
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
[PDF][PDF] Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo …
SH Khoo, R FitzGerald, G Saunders, C Middleton… - 2022 - academia.edu
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled …
AGILE CST-2 Study Group - The Lancet …, 2023 - researchportal.ukhsa.gov.uk
Background: The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled …
SH Khoo, R FitzGerald, G Saunders… - The Lancet …, 2023 - pubmed.ncbi.nlm.nih.gov
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled …
SH Khoo, R Fitzgerald, G Saunders, C Middleton… - 2023 - cabidigitallibrary.org
Background: The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled …
SH Khoo, R FitzGerald, G Saunders, C Middleton… - 2023 - repository.cam.ac.uk
BACKGROUND: The antiviral drug molnupiravir was licensed for treating at-risk patients
with COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the …
with COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the …
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled …
SH Khoo, R FitzGerald, G Saunders… - The Lancet …, 2022 - eprints.soton.ac.uk
Background: the antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled …
SH Khoo, R FitzGerald, G Saunders… - Lancet Infectious …, 2023 - archive.lstmed.ac.uk
The antiviral drug molnupiravir was licensed for treating at-risk patients with COVID-19 on
the basis of data from unvaccinated adults. We aimed to evaluate the safety and virological …
the basis of data from unvaccinated adults. We aimed to evaluate the safety and virological …